Presenter: Phillip Kuo, M.D., Ph.D. | Senior Medical Director, Invicro
The landmark phase 3 theranostic trial, “Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (VISION)”, demonstrated prolonged overall survival and radiographic progression-free survival when the targeted delivery of the beta-particle emitting radiopharmaceutical was added to standard of care. The trial incorporated novel read criteria of PSMA-PET/CT for selection of patients. The trial’s success opens the doors for utilization of PSMA-PET and molecular imaging for future theranostic trials.
During this webinar, the presenter will discuss:
Dr. Kuo is board-certified in Internal Medicine and Radiology with a special certification in Nuclear Medicine. Prior to taking on the role of Senior Medical Director for Invicro, he was Chief of Nuclear Medicine for a university medical center for 10 years. Dr. Kuo has more than 100 publications and has served as principal investigator and co-principal investigator on multiple NIH grants and investigator-initiated trials.
Dr. Kuo’s experience includes design and supervision of phase I-III clinical trials including theranostics with PET, SPECT, MRI, and radiotherapeutics. Dr. Kuo’s experience also includes participation in USFDA and EMA meetings for regulatory approval. As a reader for clinical trials, he has reviewed over ten thousand scans for oncology or neurology.
Dr. Kuo received his A.B. from Harvard University, M.D. and Ph.D. from the University of Virginia, completed his Internal Medicine Residency at UCLA Medical Center, Diagnostic Radiology Residency at Yale New Haven Hospital, and Nuclear Medicine Fellowship at Yale New Haven Hospital.